165:@0.890196:0.957873:0.914685:0.957873:0.914685:0.938882:0.890196:0.938882:0.007305:0.008593:0.008591
6:@0.941813:0.497523:0.963291:0.497523:0.963291:0.450045:0.941813:0.450045:0.021478
TARGETED LONG-READ SEQUENCING PROVIDES PERSONALIZED BIOMARKERS FOR:@0.410650:0.057372:0.882354:0.057372:0.882354:0.040253:0.410650:0.040253:0.005566:0.007919:0.008311:0.008404:0.006985:0.006387:0.006985:0.008423:0.002988:0.006481:0.008442:0.008759:0.008404:0.005155:0.008423:0.006985:0.007919:0.008423:0.002988:0.007807:0.006985:0.008442:0.008367:0.006985:0.008759:0.008255:0.003511:0.008759:0.008404:0.002988:0.008050:0.008307:0.008330:0.007620:0.003511:0.008423:0.006871:0.007807:0.002988:0.008050:0.006985:0.008348:0.007807:0.008442:0.008759:0.007919:0.006481:0.003511:0.006630:0.006985:0.008423:0.002988:0.008236:0.003511:0.008442:0.011112:0.007919:0.008423:0.008031:0.006985:0.008347:0.007807:0.002988:0.006593:0.008442:0.008423
MINIMAL RESIDUAL DISEASE TRACING IN PEDIATRIC LEUKEMIA:@0.521755:0.073247:0.882541:0.073247:0.882541:0.056128:0.521755:0.056128:0.011112:0.003511:0.008759:0.003511:0.011112:0.007919:0.006292:0.002988:0.008423:0.006873:0.007807:0.003511:0.008423:0.008255:0.007919:0.006294:0.002988:0.008423:0.003511:0.007807:0.006985:0.007712:0.007807:0.006985:0.002988:0.006387:0.008423:0.007863:0.008255:0.003511:0.008759:0.008404:0.002988:0.003511:0.008759:0.002988:0.008050:0.006985:0.008423:0.003511:0.007095:0.006387:0.008423:0.003511:0.008255:0.002988:0.006481:0.006985:0.008367:0.008031:0.006985:0.011112:0.003511:0.007919
pared. Furthermore, the implementation of additional recurrent fusion gene targets, :@0.147059:0.121273:0.886393:0.121273:0.886393:0.100900:0.147059:0.100900:0.011368:0.009085:0.007442:0.009108:0.011117:0.004497:0.007715:0.010729:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.017485:0.010843:0.007442:0.008743:0.004497:0.007715:0.006620:0.011299:0.009039:0.007715:0.005615:0.017280:0.011162:0.005182:0.009039:0.017485:0.009039:0.011391:0.006551:0.008809:0.006437:0.005547:0.010843:0.011756:0.007715:0.010843:0.006209:0.007715:0.009291:0.011322:0.011391:0.005273:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.007715:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.007715:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.007715:0.009656:0.009039:0.011596:0.009039:0.007715:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.007670:0.004497:0.004109
such as :@0.147059:0.141852:0.212366:0.141852:0.212366:0.121479:0.147059:0.121479:0.007510:0.011345:0.008765:0.011459:0.005159:0.009291:0.007670:0.004109
BCR-ABL1:@0.213430:0.142321:0.313434:0.142321:0.313434:0.120299:0.213430:0.120299:0.013399:0.014495:0.013080:0.007624:0.015157:0.013217:0.012144:0.010888
 or :@0.313433:0.141852:0.341350:0.141852:0.341350:0.121479:0.313433:0.121479:0.005159:0.010843:0.007807:0.004109
RUNX1:@0.342414:0.142321:0.412811:0.142321:0.412811:0.120299:0.342414:0.120299:0.012623:0.016139:0.016093:0.014655:0.010888
, would broaden the target population of the assay . A :@0.412811:0.141852:0.886455:0.141852:0.886455:0.121479:0.412811:0.121479:0.004497:0.005159:0.014518:0.010820:0.011550:0.005182:0.011391:0.005159:0.010818:0.007444:0.011137:0.009291:0.011322:0.009039:0.011756:0.005159:0.006620:0.011299:0.009039:0.005159:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.005159:0.011505:0.010820:0.011048:0.011550:0.005430:0.008813:0.006437:0.005545:0.010843:0.011756:0.005159:0.010845:0.006209:0.005159:0.006620:0.011299:0.009039:0.005159:0.009291:0.007533:0.007944:0.008925:0.009724:0.018298:0.004497:0.005159:0.014929:0.004109
417:@0.839517:0.134236:0.857762:0.134236:0.857762:0.122358:0.839517:0.122358:0.006082:0.006082:0.006082
prospective side-by-side comparison of current diagnostic methods and our technique :@0.147059:0.162431:0.886498:0.162431:0.886498:0.142058:0.147059:0.142058:0.011071:0.007442:0.010957:0.007510:0.011505:0.009108:0.009108:0.006437:0.005547:0.009633:0.009039:0.005102:0.007601:0.005547:0.011322:0.009039:0.007533:0.010843:0.009724:0.007533:0.007601:0.005547:0.011322:0.009039:0.005102:0.008994:0.010845:0.017280:0.011365:0.009085:0.007807:0.005615:0.007875:0.010843:0.011756:0.005113:0.010843:0.006209:0.005102:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.005113:0.011391:0.005796:0.009199:0.009861:0.011596:0.010957:0.007510:0.006437:0.005547:0.008994:0.005113:0.017485:0.009131:0.006620:0.011299:0.011276:0.011391:0.007670:0.005102:0.009085:0.011598:0.011391:0.005113:0.010820:0.011413:0.007807:0.005102:0.006209:0.009108:0.008765:0.011459:0.011756:0.005547:0.010706:0.011345:0.009039:0.004109
is required to confirm the advantages of our assay with respect to time, accuracy and :@0.147059:0.183009:0.886482:0.183009:0.886482:0.162636:0.147059:0.162636:0.005615:0.007670:0.006300:0.007442:0.009108:0.010706:0.011413:0.005615:0.007442:0.009108:0.011391:0.006300:0.006209:0.011048:0.006300:0.008994:0.010843:0.011756:0.005684:0.005684:0.007807:0.017645:0.006300:0.006620:0.011299:0.009039:0.006300:0.009291:0.011322:0.009838:0.009085:0.011391:0.006551:0.009199:0.009656:0.009039:0.007670:0.006300:0.010843:0.006209:0.006300:0.010820:0.011413:0.007807:0.006300:0.009291:0.007533:0.007944:0.008925:0.009724:0.006300:0.014723:0.005273:0.006617:0.011459:0.006300:0.007442:0.009039:0.007510:0.011505:0.009108:0.009108:0.006437:0.006300:0.006209:0.011048:0.006300:0.006437:0.005615:0.017485:0.008743:0.004497:0.006300:0.009291:0.008994:0.009106:0.011413:0.007898:0.009291:0.009382:0.009724:0.006300:0.009085:0.011596:0.011391:0.004109
sensitivity to identify appropriate MRD targets for PCR-based assays.:@0.147059:0.203588:0.726396:0.203588:0.726396:0.183215:0.147059:0.183215:0.007875:0.009039:0.011619:0.007601:0.005273:0.006437:0.005547:0.009838:0.005273:0.006437:0.009724:0.004109:0.006207:0.011048:0.004109:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.006506:0.009724:0.004109:0.008811:0.011048:0.011071:0.007442:0.010820:0.011071:0.007807:0.005798:0.008811:0.006209:0.009039:0.004109:0.019608:0.013376:0.016139:0.004109:0.006549:0.009085:0.007624:0.009656:0.009131:0.006437:0.007670:0.004109:0.006026:0.010843:0.007807:0.004109:0.012167:0.014678:0.012349:0.007533:0.011114:0.009291:0.007875:0.009108:0.011391:0.004109:0.009291:0.007533:0.007944:0.008925:0.009724:0.007670:0.004497
Taken together, we have developed a targeted nanopore sequencing assay for lymphoid :@0.147059:0.224167:0.886512:0.224167:0.886512:0.203794:0.147059:0.203794:0.010911:0.009405:0.010272:0.009039:0.011756:0.004931:0.006209:0.011048:0.009656:0.009131:0.006620:0.011299:0.009039:0.006255:0.004497:0.004931:0.014518:0.009039:0.004931:0.011391:0.008925:0.009635:0.009039:0.004931:0.011322:0.009336:0.009633:0.008948:0.005182:0.010820:0.011505:0.009108:0.011391:0.004931:0.009291:0.004931:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.004931:0.011687:0.009085:0.011596:0.010820:0.011505:0.010843:0.007442:0.009039:0.004931:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.005615:0.011459:0.009861:0.004931:0.009291:0.007533:0.007944:0.008925:0.009724:0.004931:0.006026:0.010843:0.007807:0.004931:0.005182:0.009724:0.017280:0.011162:0.011299:0.010843:0.005547:0.011391:0.004109
leukemia patients to simultaneously identify recurrent fusion genes as well as the rear-:@0.147059:0.244745:0.882353:0.244745:0.882353:0.224373:0.147059:0.224373:0.005182:0.009131:0.011550:0.010272:0.009039:0.017645:0.005798:0.009291:0.005387:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.005387:0.006209:0.011048:0.005387:0.007601:0.005615:0.017280:0.011550:0.004908:0.006551:0.009085:0.011596:0.009108:0.010820:0.011413:0.007556:0.005182:0.009724:0.005387:0.005547:0.011322:0.009039:0.011391:0.006437:0.005615:0.006503:0.009724:0.005387:0.007442:0.009108:0.009108:0.011413:0.007807:0.007442:0.009039:0.011391:0.006437:0.005387:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.005387:0.009656:0.009039:0.011596:0.009039:0.007670:0.005387:0.009291:0.007670:0.005387:0.014518:0.008948:0.005385:0.005250:0.005387:0.009291:0.007670:0.005387:0.006617:0.011302:0.009039:0.005387:0.007442:0.009291:0.009085:0.007170:0.007533
ranged Ig and TCR repertoire. Our assay detects known and novel patient specific ge-:@0.147059:0.265324:0.882353:0.265324:0.882353:0.244951:0.147059:0.244951:0.007898:0.009085:0.011459:0.009656:0.009108:0.011391:0.005718:0.006483:0.009861:0.005716:0.009085:0.011596:0.011391:0.005718:0.013057:0.014678:0.013376:0.005718:0.007442:0.009131:0.011502:0.009039:0.007967:0.006209:0.010843:0.005615:0.007442:0.008743:0.004497:0.005718:0.016504:0.011413:0.007807:0.005716:0.009291:0.007533:0.007944:0.008925:0.009724:0.005718:0.011322:0.009131:0.006209:0.009108:0.009108:0.006437:0.007670:0.005716:0.010706:0.011596:0.010866:0.014723:0.011756:0.005718:0.009085:0.011596:0.011391:0.005718:0.011596:0.010866:0.009633:0.008948:0.005250:0.005716:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.005718:0.007510:0.011505:0.009108:0.008994:0.005615:0.005684:0.005615:0.008994:0.005718:0.009656:0.009037:0.007533
nomic MRD targets within 48 hours after sequencing library initiation, a time-frame :@0.147059:0.285903:0.886528:0.285903:0.886528:0.265530:0.147059:0.265530:0.011596:0.010843:0.017645:0.005547:0.008994:0.006528:0.019608:0.013376:0.016139:0.006528:0.006551:0.009085:0.007624:0.009658:0.009128:0.006437:0.007670:0.006528:0.014723:0.005273:0.006617:0.011459:0.005615:0.011756:0.006528:0.010432:0.010432:0.006528:0.011299:0.010820:0.011413:0.007624:0.007670:0.006528:0.009085:0.006197:0.005969:0.009039:0.007807:0.006528:0.007873:0.009108:0.010706:0.011345:0.009039:0.011598:0.008994:0.005615:0.011459:0.009861:0.006528:0.005250:0.005547:0.010820:0.007898:0.009085:0.008400:0.009724:0.006528:0.005615:0.011756:0.005271:0.006437:0.005798:0.008811:0.006437:0.005547:0.010843:0.011756:0.004497:0.006528:0.009291:0.006528:0.006437:0.005615:0.017485:0.009039:0.007533:0.006412:0.007898:0.009087:0.017485:0.009039:0.004109
comparable diagnostic methods are unable to meet. :@0.147059:0.306482:0.584509:0.306482:0.584509:0.286109:0.147059:0.286109:0.008994:0.010843:0.017280:0.011368:0.009085:0.007898:0.009108:0.010911:0.005182:0.009039:0.004109:0.011391:0.005798:0.009199:0.009861:0.011596:0.010957:0.007510:0.006437:0.005547:0.008994:0.004109:0.017485:0.009131:0.006617:0.011302:0.011274:0.011391:0.007670:0.004109:0.009085:0.007444:0.009039:0.004109:0.011413:0.011685:0.009110:0.010909:0.005182:0.009039:0.004109:0.006209:0.011048:0.004109:0.017485:0.009108:0.009131:0.006437:0.004497:0.004109
Material and Methods:@0.147059:0.367231:0.377063:0.367231:0.377063:0.339121:0.147059:0.339121:0.017286:0.011040:0.010343:0.011069:0.013103:0.006217:0.012318:0.009991:0.004358:0.012318:0.013626:0.013103:0.004648:0.017286:0.011069:0.010343:0.013509:0.013132:0.013103:0.012144
Patient material:@0.147059:0.407139:0.291092:0.407139:0.291092:0.383979:0.147059:0.383979:0.010110:0.009463:0.008616:0.004856:0.009363:0.011679:0.008367:0.003984:0.014817:0.009463:0.008616:0.009363:0.011231:0.004856:0.010558:0.008691
This study was conducted in accordance with the Declaration of Helsinki and Good Clin-:@0.147059:0.432894:0.882353:0.432894:0.882353:0.412521:0.147059:0.412521:0.011470:0.011470:0.005615:0.007670:0.002922:0.007512:0.006163:0.011345:0.011322:0.009724:0.002922:0.014723:0.009291:0.007670:0.002922:0.008994:0.010843:0.011596:0.011048:0.011345:0.009108:0.006209:0.009108:0.011391:0.002922:0.005615:0.011756:0.002922:0.009291:0.008994:0.008994:0.010840:0.007444:0.011571:0.009087:0.011596:0.008994:0.009039:0.002922:0.014723:0.005273:0.006620:0.011459:0.002922:0.006620:0.011299:0.009039:0.002922:0.016230:0.009106:0.008768:0.005430:0.009085:0.007898:0.008811:0.006437:0.005547:0.010843:0.011756:0.002922:0.010843:0.006209:0.002922:0.016207:0.008948:0.005250:0.007601:0.005615:0.011870:0.010703:0.005615:0.002922:0.009085:0.011596:0.011391:0.002922:0.015819:0.011276:0.011276:0.011391:0.002922:0.014746:0.005250:0.005615:0.011687:0.007533
ical Practice, and informed consent was obtained from all patients or their guardians. :@0.147059:0.453472:0.886462:0.453472:0.886462:0.433099:0.147059:0.433099:0.005547:0.009108:0.009405:0.005250:0.006026:0.011916:0.007898:0.009291:0.009108:0.006437:0.005547:0.008994:0.008743:0.004497:0.006026:0.009085:0.011596:0.011391:0.006026:0.005615:0.011756:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.006026:0.008994:0.010843:0.011619:0.007875:0.009039:0.011391:0.006437:0.006026:0.014723:0.009291:0.007670:0.006026:0.010957:0.010797:0.006549:0.009085:0.005615:0.011596:0.009108:0.011391:0.006026:0.006414:0.007442:0.010843:0.017645:0.006026:0.009405:0.005387:0.005250:0.006026:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.007670:0.006026:0.010843:0.007807:0.006026:0.006620:0.011299:0.009039:0.005615:0.007807:0.006026:0.009861:0.011596:0.009085:0.007442:0.011391:0.005798:0.009085:0.011619:0.007670:0.004497:0.004109
Collection and use of patient material was approved by the institutional review boards of :@0.147059:0.474051:0.886416:0.474051:0.886416:0.453678:0.147059:0.453678:0.014997:0.010934:0.005387:0.005182:0.009108:0.009108:0.006437:0.005547:0.010843:0.011756:0.003607:0.009085:0.011596:0.011391:0.003607:0.011413:0.007875:0.009039:0.003607:0.010843:0.006209:0.003607:0.011368:0.008811:0.006437:0.005547:0.009039:0.011391:0.006437:0.003607:0.017577:0.008811:0.006209:0.009039:0.007807:0.005796:0.009405:0.005250:0.003607:0.014723:0.009291:0.007670:0.003607:0.008811:0.011048:0.011071:0.007442:0.010866:0.009635:0.009106:0.011391:0.003607:0.010843:0.009724:0.003607:0.006620:0.011299:0.009039:0.003607:0.005615:0.011619:0.007510:0.006437:0.005273:0.006163:0.011071:0.006437:0.005547:0.010843:0.011687:0.009405:0.005250:0.003607:0.007442:0.009336:0.009838:0.005547:0.009336:0.014723:0.003607:0.011254:0.011139:0.009085:0.007442:0.011391:0.007670:0.003607:0.010843:0.006209:0.004109
the Princess Maxima Center for Pediatric Oncology in Utrecht, the Netherlands.:@0.147059:0.494630:0.820787:0.494630:0.820787:0.474257:0.147059:0.474257:0.006620:0.011299:0.009039:0.004109:0.011916:0.007807:0.005615:0.011596:0.008994:0.009039:0.007533:0.007670:0.004109:0.019083:0.009291:0.010089:0.005615:0.017577:0.009291:0.004109:0.014995:0.009039:0.011391:0.006209:0.009039:0.007807:0.004109:0.006026:0.010843:0.007807:0.004109:0.011162:0.009108:0.011391:0.005798:0.008811:0.006437:0.007807:0.005547:0.008994:0.004109:0.016296:0.011598:0.008994:0.010934:0.005182:0.011048:0.010546:0.009724:0.004109:0.005615:0.011756:0.004109:0.015041:0.006437:0.007442:0.009108:0.008765:0.011094:0.006437:0.004497:0.004109:0.006620:0.011299:0.009039:0.004109:0.015522:0.009131:0.006620:0.011299:0.009039:0.007601:0.005433:0.009085:0.011596:0.011391:0.007670:0.004497
DNA-Isolations:@0.147059:0.529436:0.278392:0.529436:0.278392:0.506276:0.147059:0.506276:0.011231:0.011679:0.010060:0.006873:0.004856:0.010409:0.011256:0.008691:0.009463:0.008616:0.004856:0.011256:0.011679:0.010409
Genomic DNA was extracted from blood or bone marrow with the QIAamp blood mini :@0.147059:0.555190:0.886462:0.555190:0.886462:0.534817:0.147059:0.534817:0.015819:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.003664:0.015773:0.015408:0.014929:0.003661:0.014723:0.009291:0.007670:0.003664:0.009108:0.010089:0.006437:0.007896:0.009291:0.009108:0.006209:0.009108:0.011391:0.003664:0.006412:0.007444:0.010843:0.017645:0.003661:0.010911:0.005182:0.011276:0.011276:0.011391:0.003664:0.010843:0.007807:0.003661:0.011254:0.010843:0.011596:0.009039:0.003664:0.017577:0.009085:0.007807:0.007442:0.010866:0.014723:0.003664:0.014723:0.005271:0.006620:0.011459:0.003664:0.006620:0.011299:0.009039:0.003664:0.015979:0.006483:0.014700:0.009085:0.017280:0.011276:0.003661:0.010911:0.005182:0.011276:0.011276:0.011391:0.003664:0.017645:0.005615:0.011756:0.005615:0.004109
kit. Sample quality control was performed using a 4200 TapeStation System (Agilent), :@0.147059:0.575769:0.886487:0.575769:0.886487:0.555396:0.147059:0.555396:0.010706:0.005273:0.006437:0.004497:0.006049:0.010112:0.009085:0.017280:0.011162:0.005182:0.009039:0.006049:0.010706:0.011596:0.009405:0.005250:0.005273:0.006437:0.009724:0.006049:0.008994:0.010843:0.011391:0.006437:0.007442:0.010934:0.005250:0.006049:0.014723:0.009291:0.007670:0.006049:0.011505:0.009039:0.007807:0.006026:0.010843:0.007807:0.017485:0.009108:0.011391:0.006049:0.011413:0.007601:0.005615:0.011459:0.009861:0.006049:0.009291:0.006049:0.010432:0.010432:0.010432:0.010432:0.006049:0.010909:0.008813:0.011502:0.009039:0.009793:0.006551:0.008811:0.006437:0.005547:0.010843:0.011756:0.006049:0.009816:0.009724:0.007512:0.006209:0.009039:0.017645:0.006049:0.006939:0.014678:0.009861:0.005752:0.005182:0.009039:0.011391:0.006437:0.006939:0.004497:0.004109
and DNA content was measured with a Qubit 3.0 Fluorometer (Thermo Fisher).:@0.147059:0.596347:0.817705:0.596347:0.817705:0.575974:0.147059:0.575974:0.009085:0.011596:0.011391:0.004109:0.015773:0.015408:0.014929:0.004109:0.008994:0.010843:0.011391:0.006209:0.009039:0.011391:0.006437:0.004109:0.014723:0.009291:0.007670:0.004109:0.017485:0.009291:0.009291:0.007510:0.011413:0.007442:0.009108:0.011391:0.004109:0.014723:0.005271:0.006620:0.011459:0.004109:0.009291:0.004109:0.016435:0.011345:0.010820:0.005273:0.006437:0.004109:0.010432:0.004497:0.010432:0.004109:0.011137:0.004908:0.011345:0.010843:0.007442:0.010843:0.017488:0.009128:0.006209:0.009039:0.007807:0.004109:0.006825:0.011470:0.011311:0.009039:0.007807:0.017485:0.011048:0.004109:0.011391:0.005615:0.007556:0.011299:0.009039:0.007807:0.006939:0.004497
cr:@0.147059:0.629625:0.161884:0.629625:0.161884:0.614185:0.147059:0.614185:0.007338:0.007487
RNA design:@0.161883:0.631153:0.257681:0.631153:0.257681:0.607993:0.161883:0.607993:0.011231:0.011679:0.010309:0.003984:0.011231:0.009214:0.010409:0.004856:0.011206:0.011679
crRNAs  were  designed  as  previously  described .  In  brief,  the  known  target  fusion :@0.147059:0.656907:0.886465:0.656907:0.886465:0.636535:0.147059:0.636535:0.008994:0.007807:0.013376:0.015408:0.014586:0.007670:0.004109:0.004164:0.014518:0.009039:0.007442:0.009039:0.004109:0.004166:0.011322:0.009039:0.007601:0.005615:0.009861:0.011594:0.009108:0.011391:0.004109:0.004166:0.009291:0.007670:0.004109:0.004164:0.011071:0.007442:0.009336:0.009838:0.005547:0.010820:0.011413:0.007556:0.005182:0.009724:0.004109:0.004164:0.011322:0.009039:0.007875:0.008994:0.007807:0.005547:0.011254:0.009108:0.011391:0.018244:0.004497:0.004109:0.004164:0.006894:0.011756:0.004109:0.004166:0.010820:0.007807:0.005547:0.009039:0.005935:0.004497:0.004109:0.004164:0.006620:0.011299:0.009039:0.004109:0.004164:0.010706:0.011596:0.010866:0.014723:0.011756:0.004109:0.004164:0.006551:0.009087:0.007622:0.009656:0.009133:0.006437:0.004109:0.004166:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.004109
403:@0.559061:0.649291:0.577306:0.649291:0.577306:0.637414:0.559061:0.637414:0.006082:0.006082:0.006082
partners were designated as a 5’ or 3’ fusion partner, dependent upon known literature. :@0.147059:0.677486:0.886498:0.677486:0.886498:0.657113:0.147059:0.657113:0.011368:0.009085:0.007967:0.006437:0.011596:0.009039:0.007624:0.007670:0.004874:0.014518:0.009039:0.007442:0.009039:0.004885:0.011322:0.009039:0.007601:0.005615:0.009861:0.011687:0.008811:0.006209:0.009108:0.011391:0.004874:0.009291:0.007670:0.004874:0.009291:0.004885:0.010432:0.004291:0.004874:0.010843:0.007807:0.004874:0.010432:0.004291:0.004885:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.004874:0.011368:0.009085:0.007967:0.006437:0.011596:0.009039:0.006255:0.004497:0.004874:0.011322:0.009131:0.011505:0.009039:0.011596:0.011322:0.009039:0.011391:0.006437:0.004885:0.011071:0.011502:0.010845:0.011756:0.004874:0.010706:0.011596:0.010866:0.014723:0.011756:0.004874:0.005250:0.005273:0.006209:0.009039:0.007898:0.008811:0.006163:0.011413:0.007442:0.008743:0.004497:0.004109
Furthermore, the most common breakpoint locations for :@0.147059:0.698065:0.630532:0.698065:0.630532:0.677692:0.147059:0.677692:0.010729:0.011413:0.007967:0.006620:0.011299:0.009039:0.007807:0.017485:0.010843:0.007442:0.008743:0.004497:0.004063:0.006620:0.011299:0.009039:0.004063:0.017485:0.010959:0.007510:0.006437:0.004063:0.008994:0.010843:0.017645:0.017485:0.010843:0.011756:0.004063:0.010820:0.007442:0.009291:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.004063:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.004063:0.006026:0.010843:0.007807:0.004109
KMT2A SIL:@0.630455:0.698065:0.738831:0.698065:0.738831:0.677482:0.630455:0.677482:0.014244:0.019106:0.013148:0.010432:0.014427:0.008554:0.009861:0.007236:0.011368
, :@0.701810:0.698065:0.710416:0.698065:0.710416:0.677692:0.701810:0.677692:0.004497:0.004109
, and :@0.738830:0.698065:0.783571:0.698065:0.783571:0.677692:0.738830:0.677692:0.004497:0.004063:0.009085:0.011596:0.011391:0.004109
TAL1:@0.783517:0.698065:0.831294:0.698065:0.831294:0.677482:0.783517:0.677482:0.011550:0.014427:0.011368:0.010432
 genes :@0.831293:0.698065:0.886465:0.698065:0.886465:0.677692:0.831293:0.677692:0.004063:0.009656:0.009039:0.011596:0.009039:0.007670:0.004109
were extracted from a literature search and the most distal breakpoint locations were :@0.147059:0.718644:0.886414:0.718644:0.886414:0.698271:0.147059:0.698271:0.014518:0.009039:0.007442:0.009039:0.006483:0.009108:0.010089:0.006437:0.007896:0.009291:0.009108:0.006209:0.009108:0.011391:0.006483:0.006412:0.007442:0.010845:0.017645:0.006483:0.009291:0.006483:0.005250:0.005273:0.006209:0.009039:0.007898:0.008811:0.006163:0.011413:0.007442:0.009039:0.006483:0.007875:0.009291:0.009085:0.007442:0.008765:0.011459:0.006483:0.009085:0.011596:0.011391:0.006483:0.006620:0.011299:0.009039:0.006483:0.017483:0.010957:0.007512:0.006437:0.006483:0.011391:0.005615:0.007510:0.006551:0.009405:0.005250:0.006483:0.010820:0.007442:0.009288:0.009405:0.010272:0.011505:0.010843:0.005615:0.011391:0.006437:0.006483:0.005182:0.011276:0.009108:0.008811:0.006437:0.005547:0.010843:0.011619:0.007670:0.006483:0.014518:0.009039:0.007442:0.009039:0.004109
noted as extreme borders of the targeted area. For the Ig and TCR loci, crRNAs were de-:@0.147059:0.739222:0.882353:0.739222:0.882353:0.718849:0.147059:0.718849:0.011596:0.010820:0.006209:0.009108:0.011391:0.004132:0.009291:0.007670:0.004132:0.009108:0.010089:0.006437:0.007442:0.009039:0.017485:0.009039:0.004132:0.011254:0.010843:0.007442:0.011322:0.009039:0.007624:0.007670:0.004132:0.010843:0.006209:0.004132:0.006620:0.011299:0.009039:0.004132:0.006551:0.009085:0.007624:0.009656:0.009131:0.006209:0.009108:0.011391:0.004132:0.009085:0.007442:0.009291:0.009291:0.004497:0.004132:0.010683:0.010843:0.007807:0.004132:0.006620:0.011299:0.009039:0.004132:0.006483:0.009861:0.004132:0.009085:0.011598:0.011391:0.004132:0.013057:0.014678:0.013376:0.004132:0.005182:0.011274:0.008994:0.005341:0.004497:0.004132:0.008994:0.007807:0.013376:0.015408:0.014586:0.007670:0.004132:0.014518:0.009039:0.007442:0.009039:0.004132:0.011322:0.009060:0.007533
signed adjacent to J segments, directing sequencing towards the (D)V segments.There-:@0.147059:0.759801:0.882353:0.759801:0.882353:0.739428:0.147059:0.739428:0.007601:0.005615:0.009861:0.011596:0.009108:0.011391:0.005182:0.009291:0.011048:0.005273:0.009291:0.008994:0.009039:0.011391:0.006437:0.005182:0.006209:0.011048:0.005182:0.006871:0.005182:0.007875:0.009039:0.009861:0.017485:0.009039:0.011391:0.006437:0.007670:0.004497:0.005182:0.011391:0.005615:0.007442:0.009108:0.009108:0.006437:0.005615:0.011459:0.009861:0.005182:0.007875:0.009106:0.010706:0.011345:0.009039:0.011598:0.008994:0.005615:0.011459:0.009861:0.005182:0.006209:0.010866:0.014723:0.009085:0.007442:0.011391:0.007670:0.005182:0.006620:0.011299:0.009039:0.005182:0.006939:0.016139:0.006939:0.015089:0.005182:0.007873:0.009039:0.009861:0.017485:0.009039:0.011391:0.006437:0.007670:0.004497:0.011470:0.011311:0.009039:0.007442:0.008948:0.007533
fore, genomic coordinates from the first to the last J segment were defined. If the un-:@0.147059:0.780380:0.882353:0.780380:0.882353:0.760007:0.147059:0.760007:0.006026:0.010843:0.007442:0.008743:0.004497:0.006232:0.009656:0.009039:0.011596:0.010843:0.017645:0.005547:0.008994:0.006232:0.008994:0.011276:0.010843:0.007442:0.011391:0.005615:0.011687:0.008811:0.006209:0.009039:0.007670:0.006232:0.006414:0.007442:0.010843:0.017645:0.006232:0.006620:0.011299:0.009039:0.006232:0.005684:0.005684:0.007622:0.007512:0.006437:0.006232:0.006209:0.011048:0.006232:0.006620:0.011302:0.009039:0.006232:0.005433:0.009291:0.007510:0.006437:0.006232:0.006871:0.006232:0.007875:0.009039:0.009861:0.017485:0.009039:0.011391:0.006437:0.006232:0.014518:0.009039:0.007442:0.009039:0.006232:0.011322:0.009039:0.005684:0.005684:0.011596:0.009108:0.011117:0.004497:0.006232:0.006894:0.006209:0.006232:0.006620:0.011299:0.009039:0.006232:0.011413:0.011751:0.007533
known fusion partner or the V or D segments was the 5’ partner, crRNAs were designed :@0.147059:0.800958:0.886580:0.800958:0.886580:0.780585:0.147059:0.780585:0.010706:0.011596:0.010866:0.014723:0.011756:0.004109:0.006366:0.011413:0.007604:0.005545:0.010845:0.011756:0.004109:0.011368:0.009085:0.007967:0.006437:0.011596:0.009039:0.007807:0.004109:0.010843:0.007807:0.004109:0.006620:0.011302:0.009039:0.004109:0.015089:0.004109:0.010843:0.007807:0.004109:0.016139:0.004109:0.007875:0.009039:0.009861:0.017485:0.009039:0.011391:0.006437:0.007670:0.004109:0.014723:0.009291:0.007670:0.004109:0.006620:0.011299:0.009039:0.004109:0.010432:0.004291:0.004109:0.011368:0.009085:0.007967:0.006437:0.011596:0.009039:0.006255:0.004497:0.004109:0.008994:0.007807:0.013376:0.015408:0.014586:0.007670:0.004109:0.014518:0.009039:0.007442:0.009039:0.004109:0.011322:0.009039:0.007601:0.005615:0.009861:0.011596:0.009108:0.011391:0.004109
as the sequence present on the minus strand of the gene (5’->3’) until the PAM sequence. :@0.147059:0.821537:0.886377:0.821537:0.886377:0.801164:0.147059:0.801164:0.009291:0.007670:0.003629:0.006620:0.011299:0.009039:0.003629:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.009039:0.003629:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006437:0.003629:0.010843:0.011756:0.003629:0.006620:0.011299:0.009039:0.003629:0.017645:0.005615:0.011391:0.011413:0.007670:0.003629:0.007510:0.006437:0.007898:0.009085:0.011598:0.011391:0.003629:0.010843:0.006209:0.003629:0.006620:0.011299:0.009039:0.003629:0.009656:0.009039:0.011598:0.009039:0.003629:0.006939:0.010432:0.004291:0.007533:0.011550:0.010432:0.004291:0.006939:0.003629:0.011413:0.011391:0.006437:0.005752:0.005250:0.003629:0.006620:0.011299:0.009039:0.003629:0.010249:0.014929:0.019608:0.003629:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.008743:0.004497:0.004109
If the unknown fusion partner or the V or D segments was the 3’ partner, crRNAs were :@0.147059:0.842116:0.886532:0.842116:0.886532:0.821743:0.147059:0.821743:0.006894:0.006209:0.004611:0.006620:0.011299:0.009039:0.004611:0.011413:0.011870:0.010706:0.011596:0.010866:0.014723:0.011756:0.004611:0.006369:0.011413:0.007601:0.005547:0.010843:0.011756:0.004611:0.011368:0.009085:0.007967:0.006437:0.011596:0.009039:0.007807:0.004611:0.010843:0.007807:0.004611:0.006620:0.011299:0.009039:0.004611:0.015089:0.004611:0.010843:0.007807:0.004611:0.016139:0.004611:0.007873:0.009039:0.009861:0.017485:0.009039:0.011391:0.006437:0.007670:0.004611:0.014723:0.009291:0.007670:0.004611:0.006620:0.011302:0.009039:0.004611:0.010432:0.004291:0.004611:0.011368:0.009087:0.007964:0.006437:0.011596:0.009039:0.006255:0.004497:0.004611:0.008994:0.007807:0.013376:0.015408:0.014586:0.007670:0.004611:0.014518:0.009039:0.007442:0.009039:0.004109
designed as the sequence present on the plus strand of the gene (5’->3’) until the PAM :@0.147059:0.862695:0.886421:0.862695:0.886421:0.842322:0.147059:0.842322:0.011322:0.009039:0.007601:0.005615:0.009861:0.011596:0.009108:0.011391:0.005296:0.009291:0.007670:0.005296:0.006617:0.011299:0.009039:0.005296:0.007875:0.009106:0.010706:0.011345:0.009039:0.011598:0.008994:0.009039:0.005296:0.011071:0.007442:0.009039:0.007875:0.009039:0.011391:0.006437:0.005296:0.010843:0.011756:0.005296:0.006617:0.011302:0.009039:0.005296:0.011162:0.004908:0.011413:0.007670:0.005296:0.007510:0.006437:0.007898:0.009085:0.011596:0.011391:0.005296:0.010843:0.006209:0.005296:0.006620:0.011299:0.009039:0.005296:0.009658:0.009039:0.011596:0.009039:0.005296:0.006939:0.010432:0.004291:0.007533:0.011550:0.010432:0.004291:0.006939:0.005296:0.011413:0.011391:0.006437:0.005752:0.005250:0.005296:0.006620:0.011302:0.009039:0.005296:0.010249:0.014929:0.019608:0.004109
sequence. Custom Alt-R® crRNAs were chosen with maximum on-target and off-target :@0.147059:0.883273:0.886482:0.883273:0.886482:0.862900:0.147059:0.862900:0.007875:0.009108:0.010706:0.011345:0.009039:0.011596:0.008994:0.008743:0.004497:0.004908:0.014267:0.011413:0.007510:0.006209:0.010843:0.017645:0.004908:0.015066:0.004908:0.006437:0.007533:0.013376:0.005090:0.004908:0.008994:0.007807:0.013376:0.015408:0.014584:0.007670:0.004908:0.014518:0.009039:0.007442:0.009039:0.004908:0.008765:0.011302:0.010955:0.007875:0.009039:0.011756:0.004908:0.014723:0.005273:0.006620:0.011459:0.004908:0.017577:0.009291:0.010089:0.005615:0.017280:0.011413:0.017645:0.004908:0.010843:0.011756:0.007533:0.006551:0.009085:0.007624:0.009656:0.009131:0.006437:0.004908:0.009085:0.011596:0.011391:0.004908:0.010843:0.005969:0.005969:0.007533:0.006549:0.009087:0.007622:0.009658:0.009128:0.006437:0.004109
scores (IDT). :@0.147059:0.903852:0.261855:0.903852:0.261855:0.883479:0.147059:0.883479:0.007875:0.008994:0.010843:0.007442:0.009039:0.007670:0.004109:0.006939:0.007259:0.015842:0.013240:0.006939:0.004497:0.004109